Stock ENTREMED INC
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

EntreMed Inc Stock Nasdaq

Equities

US29382F2020

Pharmaceuticals

End-of-day quote Nasdaq
Other stock markets
- USD - Intraday chart for EntreMed Inc
Jul. 08 CASI Pharmaceuticals Names Daniel Lang CFO MT
Jul. 08 CASI Pharmaceuticals, Inc. Appoints Daniel Lang as CFO CI

Financials (USD)

Sales 2024 * 19.8M Sales 2025 * 46.48M Capitalization 80.92M
Net income 2024 * -35M Net income 2025 * -33M EV / Sales 2024 * 4.09 x
Net cash position 2024 * - Net cash position 2025 * - EV / Sales 2025 * 1.74 x
P/E ratio 2024 *
-2.43 x
P/E ratio 2025 *
-2.92 x
Employees -
Yield 2024 *
-
Yield 2025 *
-
Free-Float 62.32%
More Fundamentals * Assessed data

Latest news about EntreMed Inc

CASI Pharmaceuticals Names Daniel Lang CFO MT
CASI Pharmaceuticals, Inc. Appoints Daniel Lang as CFO CI
CASI Pharmaceuticals, Inc. Appoints Daniel Lang as Senior Vice President CI
Wall Street Set to Open Marginally Lower Thursday as Investors Parse Bullish Economic Data MT
US Futures Trend Lower Pre-Bell as Investors Await Slew of Economic Data MT
Top Premarket Gainers MT
CASI Pharmaceuticals Announces Plan To Submit IND Application For CID-103, an Anti-CD 38 Antibody in Antibody-Mediated Rejection, and Receipt of a Non-Binding Proposal to Acquire Entire China Business of the Company CI
Wei-Wu He proposed to acquire Business Operations in China and all license-in, distribution and related rights in Asia from CASI Pharmaceuticals, Inc. for $40 million. CI
CASI Pharmaceuticals Receives Acquisition Proposal for its Entire China Business CI
CASI Pharmaceuticals, Inc. announced that it expects to receive $15 million in funding from VR Adviser, LLC, Foresite Capital Management, LLC, Panacea Venture Management Co., Ltd. CI
Sector Update: Health Care Stocks Advance in Afternoon Trading MT
CASI Pharmaceuticals Gets FDA Clearance For Blood Disorder Study MT
CASI Pharmaceuticals Receives FDA Clearance on the Investigational New Drug Application for CID-103 in Immune Thrombocytopenia CI
Earnings Flash (CASI) CASI PHARMACEUTICALS Posts Q1 Revenue $3.4M, vs. Street Est of $12M MT
CASI Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
More news

Analyst Recommendations on EntreMed Inc

HC Wainwright Raises Price Target on CASI Pharmaceuticals to $12 From $10, Keeps Buy Rating MT
BTIG Adjusts CASI Pharmaceuticals' Price Target to $10 From $21, Keeps Buy Rating MT
CORRECTION : BTIG Lowers CASI Pharmaceuticals' Price Target to $21 From $40, Buy Rating Kept MT
HC Wainwright Lowers CASI Pharmaceuticals' Price Target to $12 From $30, Buy Rating Maintained MT
Oppenheimer Adjusts CASI Pharmaceuticals' Price Target to $35 From $6 After Reverse Stock Split, Maintains Outperform Rating MT
More recommendations

Press releases EntreMed Inc

CASI Pharmaceuticals announces appointment of Daniel Lang, MD as CFO and SVP PR
CASI Pharmaceuticals Announces Plan To Submit IND Application For CID-103, an Anti-CD 38 Antibody in Antibody-Mediated Rejection, and Receipt of a Non-Binding Proposal to Acquire Entire China Business of the Company PR
CASI Pharmaceuticals Announces $15 Million Private Placement Financing by Venrock Healthcare Capital Partners, Foresite Capital, Panacea Venture and Dr. Wei-Wu He PR
CASI Pharmaceuticals Receives FDA Clearance On The Investigational New Drug (IND) Application For CID-103 In Immune Thrombocytopenia (ITP) PR
CASI PHARMACEUTICALS ANNOUNCES FIRST QUARTER 2024 BUSINESS AND FINANCIAL RESULTS PR
More press releases

Managers and Directors - EntreMed Inc

Managers TitleAgeSince
Wei Wu He CEO
 Chief Executive Officer 59 19-04-01
Wei Zhang PSD
 President 64 18-08-31
Chun Hua Wang COO
 Chief Operating Officer 52 16-12-31
Members of the board TitleAgeSince
Wei Wu He CEO
 Chief Executive Officer 59 19-04-01
Yue Wu BRD
 Director/Board Member 62 13-03-31
Zhen Bo Su BRD
 Director/Board Member 48 23-03-20
More insiders

Company Profile

CASI Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing therapeutics and pharmaceutical products in China, the United States, and throughout the world. The Company is focused on acquiring, developing, and commercializing products that augment its hematology oncology therapeutic focus as well as other areas of unmet medical need. Its commercial product, EVOMELA, is an intravenous formulation of melphalan commercialized by Acrotech in the multiple myeloma treatment setting in the United States. Its pipeline products include CNCT19 (CD19 CAR-T), BI-1206 (anti- FcYRIIB antibody), CB-5339 (VCP/p97 inhibitor), CID-103 (Anti-CD38 Mab), Thiotepa, and Octreotide LAI. The Company’s Food and Drug Administration (FDA)-approved generic products for the China market include Entecavir tablets, Tenofovir disoproxil fumarate (TDF) tablets, Cilostazol tablets-50mg, Cilostazol tablets-100mg, Ondansetron HCL tablets, and Tizanidine tablets.
Sector
Pharmaceuticals
Calendar
2024-08-08 - Q2 2024 Earnings Release (Projected)
More about the company

Sector Other Pharmaceuticals

1st Jan change Capi.
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+62.66% 854B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+40.42% 636B
JOHNSON & JOHNSON Stock Johnson & Johnson
-4.37% 361B
MERCK & CO., INC. Stock Merck & Co., Inc.
+17.16% 324B
ABBVIE INC. Stock AbbVie Inc.
+9.87% 301B
ASTRAZENECA PLC Stock AstraZeneca PLC
+15.66% 247B
ROCHE HOLDING AG Stock Roche Holding AG
+4.21% 230B
NOVARTIS AG Stock Novartis AG
+17.90% 228B
AMGEN INC. Stock Amgen Inc.
+14.86% 177B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. CASI Stock
  4. Stock